Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis-Reference-Cited by-同舟云学术

Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis

Published:2017-11-24 Issue:24 Volume:174 Page:4797-4811
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:British Journal of Pharmacology

Author:

Jensen Brian C¹²³,Parry Traci L¹⁴,Huang Wei¹,Beak Ju Youn¹,Ilaiwy Amro⁵⁶,Bain James R⁵⁶,Newgard Christopher B⁵⁶,Muehlbauer Michael J⁵,Patterson Cam⁷,Johnson Gary L³,Willis Monte S¹⁴³^ORCID

Affiliation:

1. McAllister Heart Institute; University of North Carolina; Chapel Hill NC USA

2. Department of Internal Medicine; Division of Cardiology University of North Carolina; Chapel Hill NC USA

3. Department of Pharmacology; University of North Carolina; Chapel Hill NC USA

4. Department of Pathology & Laboratory Medicine; University of North Carolina; Chapel Hill NC USA

5. Sarah W. Stedman Nutrition and Metabolism Center, Duke Molecular Physiology Institute; Duke University Medical Center; Durham NC USA

6. Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine; Duke University Medical Center; Durham NC USA

7. Presbyterian Hospital/Weill-Cornell Medical Center; New York NY USA

Funder

American Heart Association

Leducq Foundation Transatlantic Networks of Excellence

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bph.14062/fullpdf

Reference43 articles.

1. The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors;Alexander;Br J Pharmacol,2015

2. Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial;Azuma;Clin Cardiol,1985

3. Non-targeted metabolomics of Brg1/Brm double-mutant cardiomyocytes reveals a novel role for SWI/SNF complexes in metabolic homeostasis;Banerjee;Metabolomics,2015

4. Effect of taurine supplementation on exercise capacity of patients with heart failure;Beyranvand;J Cardiol,2011

5. Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?;Brandi;Liver Int,2013

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium‐Glucose Co‐Transporter‐2 Inhibitor Empagliflozin Attenuates Sorafenib‐Induced Myocardial Inflammation and Toxicity;Environmental Toxicology;2024-06-17

2. Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications;Drug Design, Development and Therapy;2024-03

3. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond;Biomolecules;2024-02-07

4. Sorafenib induces cardiotoxicity through RBM20-mediated alternative splicing of sarcomeric and mitochondrial genes;Pharmacological Research;2023-12

5. In Silico Screening and Molecular Dynamics Simulations against Tyrosine-protein Kinase Fyn Reveal Potential Novel Therapeutic Candidates for Bovine Papillomatosis;Current Medicinal Chemistry;2023-10-19